Amgen advances MariTide obesity drug into Phase 3 trials
FROM THE WIRE · FINANCE.YAHOO.COM
Amgen (NasdaqGS:AMGN) has advanced its obesity drug candidate MariTide into Phase 3 clinical trials, targeting the growing anti-obesity treatment market. The firm is positioning MariTide to compete with existing anti-obesity therapies from established players such as Eli Lilly…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralProgress of an anti-obesity drug can shift expectations in the obesity therapy market where Lilly and Novo Nordisk compete.AI-generated summary
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Amgen Inc.438.42 USD-1.20%today -1.23%Positive Eli Lilly and Company1,368.13 USD+0.16%today -1.06%Negative Novo Nordisk A/S39.27 USD+0.04%today -0.42%Negative
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets